Dietary fucoidan synergistically reduced cell growth in the OE33 cell line when it was combined with lapatinib, a targeted therapy that acts as a tyrosine kinase inhibitor in advanced HER2-positive breast cancer cells [65]. Here, ERBB2 is linked to breast cancer.